The Effect of Transcranial Direct Current Stimulation on Relapse, Anxiety, and Depression in Patients With Opioid Dependence Under Methadone Maintenance Treatment: A Pilot Study.
anxiety
depression
opioid dependence
relapse
stress
transcranial direct current stimulation
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2020
2020
Historique:
received:
26
11
2019
accepted:
17
03
2020
entrez:
21
4
2020
pubmed:
21
4
2020
medline:
21
4
2020
Statut:
epublish
Résumé
Patients under methadone maintenance therapy (MMT) are susceptible to several complications including mental disturbances and risk of relapse. The present study was designed to evaluate the effects of tDCS on relapse, depression, and anxiety of opioid-dependent patients under methadone maintenance treatment (MMT). It was a randomized-clinical trial that conducted among 27 male patients referred to the outpatient addiction clinic of Ibn-e-Sina psychiatric hospital in Mashhad from July 2018 to May 2019. Participants were allocated to two treatment groups including intervention and sham groups. The intervention group received seven sessions of tDCS, in the F3 (cathode) and F4 (anode) areas of the brain, each one lasts 20 min, in two consecutive weeks. Depression, anxiety, and stress scale-21 (DASS-21) were measured before, during, and after the intervention in patients under MMT. Relapse on the morphine, cannabis, and methamphetamine was screened by urine dipstick tests of morphine, cannabis, and methamphetamine. Depression, anxiety, and stress of participants were significantly reduced in the intervention group compared with the control after the seventh session of tDCS (P < 0.001, P=0.01, and P=0.01, respectively). In addition, the relapse rate showed no significant changes between the two groups (P=0.33). Overall, our study demonstrated that depression, anxiety, and stress of participants were significantly reduced after the seventh session of tDCS, but did not affect on the relapse rate. Therefore, it can be applied as a safe and effective technique to relieve mental disorder among receiving MMT. http://www.irct.ir, identifier IRCT20180604039979N1.
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
Patients under methadone maintenance therapy (MMT) are susceptible to several complications including mental disturbances and risk of relapse. The present study was designed to evaluate the effects of tDCS on relapse, depression, and anxiety of opioid-dependent patients under methadone maintenance treatment (MMT).
METHODS
METHODS
It was a randomized-clinical trial that conducted among 27 male patients referred to the outpatient addiction clinic of Ibn-e-Sina psychiatric hospital in Mashhad from July 2018 to May 2019. Participants were allocated to two treatment groups including intervention and sham groups. The intervention group received seven sessions of tDCS, in the F3 (cathode) and F4 (anode) areas of the brain, each one lasts 20 min, in two consecutive weeks. Depression, anxiety, and stress scale-21 (DASS-21) were measured before, during, and after the intervention in patients under MMT. Relapse on the morphine, cannabis, and methamphetamine was screened by urine dipstick tests of morphine, cannabis, and methamphetamine.
RESULTS
RESULTS
Depression, anxiety, and stress of participants were significantly reduced in the intervention group compared with the control after the seventh session of tDCS (P < 0.001, P=0.01, and P=0.01, respectively). In addition, the relapse rate showed no significant changes between the two groups (P=0.33).
CONCLUSION
CONCLUSIONS
Overall, our study demonstrated that depression, anxiety, and stress of participants were significantly reduced after the seventh session of tDCS, but did not affect on the relapse rate. Therefore, it can be applied as a safe and effective technique to relieve mental disorder among receiving MMT.
CLINICAL TRIAL REGISTRATION
BACKGROUND
http://www.irct.ir, identifier IRCT20180604039979N1.
Identifiants
pubmed: 32308624
doi: 10.3389/fphar.2020.00401
pmc: PMC7145941
doi:
Types de publication
Journal Article
Langues
eng
Pagination
401Informations de copyright
Copyright © 2020 Sadeghi Bimorgh, Omidi, Ghoreishi, Rezaei Ardani, Ghaderi and Banafshe.
Références
Clin Chem. 1992 Aug;38(8B Pt 2):1530-1
pubmed: 1643734
Child Adolesc Psychiatr Clin N Am. 2016 Jul;25(3):549-65
pubmed: 27338974
PLoS One. 2015 Aug 12;10(8):e0135371
pubmed: 26267861
Front Pharmacol. 2018 Oct 23;9:1198
pubmed: 30405414
J Affect Disord. 2014 Jun;162:43-9
pubmed: 24767004
BMC Psychiatry. 2011 Feb 12;11:25
pubmed: 21314980
Curr Behav Neurosci Rep. 2016 Jun;3(2):95-101
pubmed: 29479515
Neuropsychol Rev. 2019 Mar;29(1):116-138
pubmed: 30536145
J Physiol Paris. 2013 Dec;107(6):493-502
pubmed: 23891741
Drug Alcohol Depend. 2008 Jan 1;92(1-3):55-60
pubmed: 17640830
Clin Psychopharmacol Neurosci. 2016 Nov 30;14(4):330-337
pubmed: 27776384
Environ Health Prev Med. 2019 May 15;24(1):34
pubmed: 31092202
Biol Psychiatry. 2008 Jun 1;63(11):1005-6
pubmed: 18482610
Electron Physician. 2017 Sep 25;9(9):5354-5362
pubmed: 29038721
Subst Abuse Treat Prev Policy. 2019 Feb 20;14(1):8
pubmed: 30786894
J ECT. 2019 Sep;35(3):201-206
pubmed: 30664050
Iran J Public Health. 2013 Oct;42(10):1139-44
pubmed: 26060622
Int J Drug Policy. 2017 Jun;44:50-57
pubmed: 28445835
Subst Use Misuse. 2018 May 12;53(6):1030-1040
pubmed: 29172870
Clin Neurophysiol. 2015 Nov;126(11):2181-8
pubmed: 25922128
Basic Clin Neurosci. 2019 Jan-Feb;10(1):59-72
pubmed: 31031894
Addict Health. 2018 Jul;10(3):173-179
pubmed: 31105915
Brain Sci. 2018 May 06;8(5):
pubmed: 29734768
J ECT. 2019 Sep;35(3):207-211
pubmed: 30844881
Liver Transpl. 2007 Nov;13(11 Suppl 2):S59-64
pubmed: 17969089
Curr Opin Psychiatry. 2008 Jan;21(1):14-8
pubmed: 18281835
Psychiatr Ann. 2008 Nov 1;38(11):nihpa128505
pubmed: 19668349
Brain Stimul. 2012 Jul;5(3):175-195
pubmed: 22037126
Brain Stimul. 2014 Nov-Dec;7(6):813-6
pubmed: 25442152
J Stud Alcohol Drugs. 2011 Jan;72(1):151-7
pubmed: 21138705
J Addict Med. 2016 May-Jun;10(3):196-201
pubmed: 27159345
Curr Behav Neurosci Rep. 2015 Sep;2(3):146-153
pubmed: 26525751
Neuropsychiatr Dis Treat. 2020 Jan 14;16:161-169
pubmed: 32021208
Int J Neuropsychopharmacol. 2015 Jun 10;18(12):
pubmed: 26065432
J Psychiatr Res. 2016 Aug;79:1-3
pubmed: 27115508
Int J Neuropsychopharmacol. 2014 Jan;17(1):53-61
pubmed: 24060107
Addiction. 2016 Oct;111(10):1836-47
pubmed: 27177849
J Subst Abuse Treat. 2005;28 Suppl 1:S63-72
pubmed: 15797640